Literature DB >> 32406000

Cardiovascular events prediction by left ventricular longitudinal strain and serum high-sensitivity troponin I in patients with axial spondyloarthritis.

Yan Chen1,2, Yap-Hang Chan1, Ho-Yin Chung3, Mei-Zhen Wu1, Yu-Juan Yu1, Kang-Li Pi1, Chak-Sing Lau3, Hung-Fat Tse1,4, Kai-Hang Yiu5,6.   

Abstract

OBJECTIVE: Patients with axial spondyloarthritis (SpA) are subjected to elevated cardiovascular risks, but assessment of early myocardial damage and clinical risk stratification remained obscure. The aim of this study was to evaluate the prognostic value of speckle-tracking strain analysis and serum high-sensitivity troponin I (hsTnI) in patients with axial SpA.
METHODS: Two-dimensional speckle-tracking echocardiography was performed to derive longitudinal strain (LS), circumferential strain (CS), and radial strain (RS). Serum hsTnI was measured by validated immunoassay (Architect i1000SR Abbott) as indicator of subclinical myocardial damage.
RESULTS: The mean Bath Ankylosing Spondylitis Disease Activity Index and median modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) were 3.8 and 15.5, respectively. Over a median follow-up of 81 months, major adverse cardiovascular events (MACE) occurred in 13% of subjects (n = 116). Univariate Cox regression showed that age, disease duration, Bath Ankylosing Spondylitis Functional Index, modified Schober test, mSASSS, hsTnI, interventricular septal thickness, E/E', LS, RS, and carotid intima-media thickness were significant predictors of MACE (all P < 0.05). After adjustment for age, sex, and statistically significant disease-related parameters, only subclinically raised hsTnI and impaired LS remained independent predictors for MACE. Kaplan-Meier analysis showed that combined impaired LS ≥ - 17.5% and hsTnI ≥ 3.0 pg/ml significantly predicted MACE (log-rank test P < 0.01; sensitivity 50%; specificity 90%; positive predictive value 43%; negative predictive value 92%).
CONCLUSIONS: Depressed LS indicating subclinical left ventricular systolic dysfunction and elevated serum hsTnI both independently predicted MACE among young patients with axial SpA. Combined analysis of speckle-tracking-derived strain analysis and serum hsTnI improves risk stratification in these patients. Key Points • Both depressed longitudinal strain (LS) and elevated serum high-sensitivity troponin I (hsTnI) are promising independent predictors for cardiovascular (CV) events in axial SpA. • Importantly, patients with LS ≥ - 17.5% and hsTnI ≥ 3.0 pg/ml had the highest risk of incident MACE. • Axial SpA patients with concomitant impaired LS and raised hsTnI are at a high risk of CV events.

Entities:  

Keywords:  Axial spondyloarthritis; High-sensitivity troponin I; Left ventricular longitudinal strain; Major adverse cardiovascular events

Mesh:

Substances:

Year:  2020        PMID: 32406000     DOI: 10.1007/s10067-020-05112-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  28 in total

1.  Atherosclerotic disease in axial spondyloarthritis: increased frequency of carotid plaques.

Authors:  Javier Rueda-Gotor; Alfonso Corrales; Ricardo Blanco; Patricia Fuentevilla; Virginia Portilla; Rosa Expósito; Cristina Mata; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Clin Exp Rheumatol       Date:  2015-05-25       Impact factor: 4.473

Review 2.  Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.

Authors:  Orit Schieir; Cedomir Tosevski; Richard H Glazier; Sheilah Hogg-Johnson; Elizabeth M Badley
Journal:  Ann Rheum Dis       Date:  2017-02-20       Impact factor: 19.103

3.  Insights into cardiac involvement in ankylosing spondylitis from cardiovascular magnetic resonance.

Authors:  P Stefan Biesbroek; Sjoerd C Heslinga; Thelma C Konings; Irene E van der Horst-Bruinsma; Mark B M Hofman; Peter M van de Ven; Otto Kamp; Vokko P van Halm; Mike J L Peters; Yvo M Smulders; Albert C van Rossum; Mike T Nurmohamed; Robin Nijveldt
Journal:  Heart       Date:  2016-11-16       Impact factor: 5.994

4.  Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy.

Authors:  Fleur M van der Valk; Sophie J Bernelot Moens; Simone L Verweij; Aart C Strang; Aart J Nederveen; Hein J Verberne; Michael T Nurmohamed; Dominique L Baeten; Erik S G Stroes
Journal:  Ann Rheum Dis       Date:  2016-04-15       Impact factor: 19.103

5.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Authors:  S Garrett; T Jenkinson; L G Kennedy; H Whitelock; P Gaisford; A Calin
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

6.  Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system.

Authors:  M C W Creemers; M J A M Franssen; M A van't Hof; F W J Gribnau; L B A van de Putte; P L C M van Riel
Journal:  Ann Rheum Dis       Date:  2004-03-29       Impact factor: 19.103

Review 7.  2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice.

Authors:  Charles V Pollack; Eugene Braunwald
Journal:  Ann Emerg Med       Date:  2007-11-26       Impact factor: 5.721

8.  Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases.

Authors:  A G Semb; E Ikdahl; J Hisdal; I C Olsen; S Rollefstad
Journal:  Int J Cardiol       Date:  2016-08-07       Impact factor: 4.164

9.  ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.

Authors:  D van der Heijde; E Lie; T K Kvien; J Sieper; F Van den Bosch; J Listing; J Braun; R Landewé
Journal:  Ann Rheum Dis       Date:  2008-12-05       Impact factor: 19.103

10.  Predictive value of high-sensitivity troponin-I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus.

Authors:  Kai-Hang Yiu; Kui-Kai Lau; Chun-Ting Zhao; Yap-Hang Chan; Yan Chen; Zhe Zhen; Arthur Wong; Chu-Pak Lau; Hung-Fat Tse
Journal:  Cardiovasc Diabetol       Date:  2014-03-25       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.